Milestone Pharmaceuticals Inc. Common Shares
MISTMilestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for cardiovascular diseases and acute care conditions. Founded to address unmet medical needs, the company leverages its expertise in clinical research and drug development to bring novel treatments to market. Its pipeline includes products aimed at improving patient outcomes in areas such as arrhythmias and other acute cardiovascular events.
Company News
Milestone Pharmaceuticals Inc. granted 288,000 stock options to six new employees as a material inducement for hiring. The options have an exercise price of $1.32 per share and vest over four years, with 25% vesting after one year followed by monthly installments. The grants were made under the company's 2021 Inducement Plan in compliance with Na...
Milestone Pharmaceuticals announced the RESET-PSVT registry, a Phase 4 observational study designed to generate real-world evidence on CARDAMYST (etripamil) nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) in adults. The study, led by Duke Clinical Research Institute, will enroll approximately 450 patients across 20 sites b...
Milestone Pharmaceuticals received FDA approval for CARDAMYST, the first self-administered nasal spray for treating paroxysmal supraventricular tachycardia (PSVT) in adults, offering a novel at-home treatment option for over 2 million Americans with this heart condition.
Milestone Pharmaceuticals presented clinical trial data for etripamil nasal spray, showing consistent efficacy and safety in treating paroxysmal supraventricular tachycardia (PSVT) across multiple studies, with a New Drug Application currently under FDA review.
Milestone Pharmaceuticals will present research data on etripamil, a potential treatment for paroxysmal supraventricular tachycardia, at the American Heart Association Scientific Sessions in New Orleans in November 2025.
